Sign In
Buy OVID
$2.40
-0.0800 (-3.23%)
At Close: Jun 05, 2026
Investors who lost money on Ovid Therapeutics Inc. should contact Levi & Korsinsky about an ongoing investigation - OVID
04:45pm, Sunday, 30'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
04:17pm, Sunday, 30'th Jun 2024
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are
OVID ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Ovid Therapeutics Inc. Investment
07:30am, Friday, 28'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o
Lost Money on Ovid Therapeutics Inc.(OVID)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
03:50pm, Wednesday, 26'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
02:45pm, Wednesday, 26'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ:OVID). Such investors are advised t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
03:56pm, Monday, 24'th Jun 2024
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
10:40am, Saturday, 22'nd Jun 2024
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
10:55am, Tuesday, 18'th Jun 2024
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
12:38pm, Monday, 17'th Jun 2024
Ovid Therapeutics (NASDAQ: OVID ) stock is falling hard on Monday after the company announced results from a Phase 3 clinical trial conducted by Takeda Pharmaceutical Company Limited. Takeda Pharmaceu
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
08:58am, Monday, 17'th Jun 2024
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndro
Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat
06:55am, Monday, 17'th Jun 2024
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and b
3 Sorry Penny Stocks to Sell in May While You Still Can
01:09pm, Tuesday, 28'th May 2024
Investors should focus on these penny stocks to sell in May to avoid potential losses. While more affordable and often appealing to investors with limited capital, Penny stocks can also carry signific
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
06:00am, Monday, 20'th May 2024
No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.
Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to Earn Q2 2024 Earnings of ($0.25) Per Share
01:38am, Monday, 20'th May 2024
Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings per share estimates for Ovid Therapeutics in a research report issu
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
10:11am, Tuesday, 14'th May 2024
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.
